In a review of records assessing patients with type 2 diabetes, researchers provide a comprehensive detail of strategies leading to diabetes remission though gaps persist.
News|Articles|May 5, 2026
GLP-1s Made Up Eight Of Every 100 Prescriptions Filled in March 2026
Author(s)Ashley Gallagher, MA
GLP-1 prescriptions surge to nearly 8% of fills, fueled by weight-loss demand.
Advertisement
Advertisement
In a shift that is redefining the landscape of modern pharmacy, nearly 8 out of every 100 prescriptions filled in March 2026 were for glucagon-like peptide-1 (GLP-1) receptor agonists. This milestone follows the largest quarter-over-quarter percentage point increase in GLP-1 RA prescribing observed since tracking began in 2019. For pharmacists on the front lines, these numbers reflect a massive acceleration in patient demand that continues to test the limits of supply chains and clinical management.
Related to this article
Exploring the effects of weight-loss and GLP-1 therapies, researchers determine the specific metabolic determinants that lead to patients’ weight reduction.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
Among patients with type 2 diabetes, researchers explore the effects of selecting additional therapy for GLP-1 treatment.
Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.
The LATA trial found long-acting cabotegravir–rilpivirine is better than daily oral therapy at keeping adolescents virologically suppressed.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Advertisement
Advertisement